NCT05914194View on ClinicalTrials.gov

A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Narcolepsy Type 1Narcolepsy With Cataplexy
Interventions
DRUG

NLS-2

Participants will receive NLS-2 tablets orally.

DRUG

Placebo

Participants will receive NLS-2 matching placebo tablets orally.

Sponsors

Lead Sponsor

NLS Pharmaceutics
All Listed Sponsors
lead

NLS Pharmaceutics

INDUSTRY